Trevi Therapeutics, Inc.
TRVI
$7.55
$0.060.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.99% | -41.06% | -64.84% | -65.68% | -41.94% |
| Total Depreciation and Amortization | 4.20% | 7.19% | 19.51% | 39.81% | 85.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | 38.79% | -3.23% |
| Total Other Non-Cash Items | 81.72% | 198.29% | 426.72% | 4,408.33% | 565.70% |
| Change in Net Operating Assets | -69.12% | 233.11% | 277.46% | 222.16% | 156.21% |
| Cash from Operations | -30.18% | -21.44% | -20.64% | -10.68% | 0.58% |
| Capital Expenditure | 89.71% | 56.25% | 74.45% | 78.35% | 73.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -212.46% | -155.01% | -136.08% | 1,121.38% | 205.24% |
| Cash from Investing | -212.79% | -155.19% | -136.23% | 981.54% | 203.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 41.27% | 98.65% | 98.67% | 98.87% | 99.03% |
| Issuance of Common Stock | 2,472.02% | 3,832.22% | 3,226.67% | 136.49% | -88.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -156.52% | 8.64% | -- | 78.75% | 12.21% |
| Cash from Financing | 2,602.77% | 1,226.17% | 877.29% | 238.30% | -86.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13,293.28% | 157.55% | -91.42% | 75.59% | 92.79% |